...
首页> 外文期刊>International Journal of Pharmaceutics >Specific gene transfer mediated by galactosylated poly-L-lysine into hepatoma cells.
【24h】

Specific gene transfer mediated by galactosylated poly-L-lysine into hepatoma cells.

机译:半乳糖基化的聚-L-赖氨酸介导的特定基因转移到肝癌细胞中。

获取原文
获取原文并翻译 | 示例
           

摘要

Plasmid DNA/galactosylated poly-L-lysine(GalPLL) complex was used to transfer luciferase reporter gene in vitro into human hepatoma cells by a receptor-mediated endocytosis process. DNA was combined with galPLL via charge interaction (DNA:GalPLL:fusogenic peptide, 1:0.4:5, w/w/w) and the resulting complex was characterized by dynamic light scattering, gel retardation assay and zeta potential analyzer to determine the particle size, electrostatic charge interaction, and apparent surface charge. The complex was tested for the efficiency of gene transfer in cultured human hepatoblastoma cell line Hep G2 and fibroblast cells NIH/3T3 in vitro. The mean diameter of the complex (DNA:GalPLL=1:0.4, w/w) was 256+/-34.8 nm, and at this ratio, it was positively charged (zeta potential of this complex was 10.1 mV). Hep G2 cells, which express a galactose specific membrane lectin, were efficiently and selectively transfected with the RSV Luc/GalPLL complex in a sugar-dependent manner. NIH/3T3 cells, which do not express the galactose-specific membrane lectin, showed only a marginal level of gene expression. The transfection efficiency of GalPLL-conjugated DNA complex into Hep G2 cells was greatly enhanced in the presence of fusogenic peptide that can disrupt endosomes, where the GalPLL-DNA complex is entrapped with the fusogenic peptide. With the fusogenic peptide KALA, the luciferase activity in Hep G2 cells was ten-fold higher than that of cells transfected in the absence of the fusogenic peptide. Our gene transfer formulation may find potential application for the gene therapy of liver diseases.
机译:质粒DNA /半乳糖基化聚-L-赖氨酸(GalPLL)复合物用于通过受体介导的内吞作用过程将萤光素酶报告基因体外转移到人肝癌细胞中。通过电荷相互作用(DNA:GalPLL:融合肽,1:0.4:5,w / w / w)将DNA与galPLL结合,并通过动态光散射,凝胶阻滞测定法和zeta电势分析仪对所得复合物进行表征,从而确定颗粒尺寸,静电荷相互作用和表观表面电荷。测试了该复合物在体外培养的人肝母细胞瘤细胞系Hep G2和成纤维细胞NIH / 3T3中基因转移的效率。该复合物的平均直径(DNA:GalPLL = 1:0.4,w / w)为256 +/- 34.8nm,并且以该比率带正电(该复合物的ζ电势为10.1mV)。表达半乳糖特异性膜凝集素的Hep G2细胞以糖依赖性方式被RSV Luc / GalPLL复合物有效和选择性地转染。不表达半乳糖特异性膜凝集素的NIH / 3T3细胞仅显示了少量的基因表达。在存在会破坏内体的融合肽的情况下,GalPLL共轭DNA复合物转入Hep G2细胞的转染效率大大提高,其中GalPLL-DNA复合物被融合在融合肽中。使用融合肽KALA,Hep G2细胞中的荧光素酶活性比没有融合肽的情况下转染的细胞高10倍。我们的基因转移制剂可能会在肝病的基因治疗中找到潜在的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号